When it comes to GLP-1 and bone loss, osteoporosis does not have to be inevitable
However, not only will double-dosing not make up for a missed dose, but it also comes with serious health risks
However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated
In terms of overall business developments, the single biggest update from Lilly's latest report is that the FDA approved Foundayo as the first oral GLP-1 agonist for obesity that can be taken at any time of day and without any restrictions related to food or water
Its one thing to say that, theoretically, GLP-1s should help make everyones body a little healthier and therefore help them live longer, or that these drugs can stop serious health conditions before they start
K., Thyssen J